Allergan Statement Regarding Florida Reports
(IRVINE, Calif., November 29, 2004) - At this time, Allergan, Inc. (NYSE: AGN) cannot determine whether the stories involving patients treated at the Advanced Integrated Medical Center in Fort Lauderdale, Florida have anything to do with Allergan's product BOTOX® (botulinum toxin type A).
We are working diligently with the appropriate public health authorities to determine the facts surrounding these cases.
BOTOX® is one of the most widely researched medicines in the world with 20 approved indications in more than 70 countries and has treated millions of patients worldwide. Its proven 15-year efficacy and safety profile, which is supported by placebo-controlled clinical trials involving more than 10,000 patients, as well as open-label studies and extensive clinical practice involving millions of patients, demonstrates the benefits of this unique and versatile therapy.
About Allergan, Inc.
Allergan, Inc., with headquarters in Irvine, California, is a technology-driven, global health care company providing specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care, neuromodulator, skin care and other specialty markets that deliver value to its customers, satisfy unmet medical needs, and improve patients' lives.
Allergan Contacts:
Jim Hindman (714) 246-4636 (investors)
Joann Bradley (714) 246-4766 (investors)
Ashwin Agarwal (714) 246-4582 (investors)
Stephanie Fagan (714) 246-5232 (media)